WASHINGTON, June 24, 2009 (GLOBE NEWSWIRE) -- Finkelstein Thompson LLP is investigating potential shareholder claims arising from the proposed acquisition of Monogram Biosciences, Inc. ("Monogram" or the "Company") (Nasdaq:MGRM) by Laboratory Corporation of America Holdings ("Labcorp") (NYSE:LH). Under the terms of the merger agreement, Monogram shareholders will receive $4.55 per share, for a total deal value of approximately $155 million.
The investigation is focused on the potential unfairness of the merger price and of the process by which the Monogram Board of Directors approved the agreement.
If you are interested in discussing your rights as a Monogram shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at contact@finkelsteinthompson.com.
Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in connection with securities and other finance-related litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers. To learn more about Finkelstein Thompson LLP, please visit our web site at www.finkelsteinthompson.com.